mTOR Pathway Expression as Potential Predictive Biomarker in Patients with Advanced Neuroendocrine Tumors Treated with Everolimus

mTOR Pathway Expression as Potential Predictive Biomarker in Patients with Advanced Neuroendocrine Tumors Treated with Everolimus

Background. Everolimus (Eve), which is a mammalian target of Rapamicin (mTOR) inhibitor, is part of the therapeutic armamentarium of neuroendocrine tumors (NETs). Currently, there are no validated biomarkers predicting Eve efficacy in NETs. In this study, we explore whether the expression of phospho...

Full description

Bibliographic Details
Main Authors: Fabio Gelsomino, Andrea Casadei-Gardini, Francesco Caputo, Giulio Rossi, Federica Bertolini, Tiziana Petrachi, Andrea Spallanzani, Elisa Pettorelli, Shaniko Kaleci, Gabriele Luppi
Format: Article
Language:English
Published: MDPI AG 2020-05-01
Series:Cancers
Subjects:
neuroendocrine tumors
everolimus
mTOR inhibitor
survival prediction
prognosis
Online Access:https://www.mdpi.com/2072-6694/12/5/1201

Internet

https://www.mdpi.com/2072-6694/12/5/1201

Similar Items